Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | KDM6B | O15054 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19838598 | 0.83 | TDP1 (0.47) | P2RX1KDM4CALDH1A1KDM4EKDM6B | |
| SCHEMBL30758512 | 0.83 | TDP1 (0.47) | P2RX1KDM4CALDH1A1KDM4EKDM6B | |
| SCHEMBL28255112 | 0.82 | KDM4C (0.47) | P2RX1KDM4CALDH1A1KDM4EKDM6B | |
| SCHEMBL28317597 | 0.82 | TDP1 (0.50) | KDM4CALDH1A1KDM4EKDM6BMEN1 | |
| SCHEMBL2562774 | 0.80 | KDM4C (0.61) | P2RX1KDM4CALDH1A1KDM4EKDM6B | |
| SCHEMBL29822292 | 0.80 | KDM4C (0.61) | P2RX1KDM4CALDH1A1KDM4EKDM6B | |
| SCHEMBL1885868 | 0.78 | TDP1 (0.52) | KDM4CALDH1A1KDM4EKDM6BMEN1 | |
| SCHEMBL16414446 | 0.78 | KDM4C (0.44) | KDM4CALDH1A1KDM4EKDM6BMEN1 | |
| SCHEMBL2645253 | 0.78 | TDP1 (0.57) | P2RX1KDM4CALDH1A1KDM4EKDM6B | |
| SCHEMBL22810576 | 0.78 | P2RX1 (0.44) | P2RX1KDM4CALDH1A1KDM4EKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-12-05 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| WO-2024140431-A1 | COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF | IONGEN THERAPEUTICS CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| CN-117384124-A | HDAC inhibitors, compositions and uses thereof | 安徽中医药大学 | 2024-01-12 | — | — | CN | disclosed |
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2006100413-A9 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | FOURNIER LAB SA (FR) | 2007-10-18 | — | — | WO | disclosed |
| WO-2006100413-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2006-09-28 | — | — | WO | disclosed |
| EP-0362771-B1 | Use of photochromic substances | RODENSTOCK OPTIK G (DE) | 2000-05-31 | — | — | EP | disclosed |
| US-5637709-A | Photochromatic substances | OPTISCHE WERKE G. RODENSTOCK (DE) | 1997-06-10 | — | — | US | disclosed |
| US-5608065-A | ADAMANTANEOSPIRO-HETEROAROMATIC PYRANS | OPTISCHE WERKE G. RODENSTOCK (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0308792-B1 | AZACHROMANE DERIVATIVES | MERCK PATENT GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
| US-4931454-A | Azachroman derivatives with effects on the cardiovascular system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-06-05 | — | — | US | disclosed |
| EP-0362771-A1 | Photochromic substances | Optische Werke G. Rodenstock (DE) | 1990-04-11 | — | — | EP | disclosed |
| WO-1990003379-A1 | PHOTOCHROMIC SUBSTANCES | OPTISCHE WERKE G. RODENSTOCK (DE) | 1990-04-05 | — | — | WO | disclosed |
| EP-0308792-A2 | Azachromane derivatives | MERCK PATENT GmbH (DE) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | P2RX1 1452/4885KDM4C 2225/4885ALDH1A1 4004/4885 |
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | SLC5A2, SLC5A1, GPR119 | P2RX1 3422/4885KDM4C 1598/4885ALDH1A1 827/4885 |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | SLC5A2, SLC5A1, GPR119 | P2RX1 3473/4885KDM4C 1666/4885ALDH1A1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.